Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Stoke Therapeutics Inc Market Cap
From what 9 stock analysts predict, the share price for Stoke Therapeutics Inc (STOK) might increase by 84.03% in the next year. This is based on a 12-month average estimation for STOK. Price targets go from $15 to $35. The majority of stock analysts believe STOK is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 9 Wall Street analysts have assigned STOK 8 buy ratings, 1 hold ratings, and 0 sell ratings. This means that analysts expect Stoke Therapeutics Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on STOK. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of STOK.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Joseph Stringer Needham | Buy | $22 | Reiterates | Nov 6, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $35 | Reiterates | Nov 6, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $35 | Reiterates | Sep 11, 2024 |
| Joseph Stringer Needham | Buy | $22 | Reiterates | Aug 8, 2024 |
| Laura Chico Wedbush | Outperform | $17 | Reiterates | Jul 11, 2024 |
| Joseph Stringer Needham | Buy | $22 | Reiterates | Jun 28, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $35 | Reiterates | May 7, 2024 |
| Sumant Kulkarni Canaccord Genuity | Buy | $20 | Maintains | May 7, 2024 |
| Joseph Stringer Needham | Buy | $22 | Reiterates | May 6, 2024 |
| Joseph Stringer Needham | Buy | $22 | Reiterates | Apr 11, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | Reiterates | Apr 4, 2024 | |
| Andrew Fein HC Wainwright & Co. | Buy | $35 | Reiterates | Mar 26, 2024 |
| Laura Chico Wedbush | Outperform | $17 | Maintains | Mar 26, 2024 |
| Sumant Kulkarni Canaccord Genuity | Buy | $21 | Maintains | Mar 26, 2024 |
| Jessica Fye JP Morgan | Neutral | $13 | Maintains | Mar 26, 2024 |
| Yaron Werber TD Cowen | Buy | Upgrade | Mar 26, 2024 | |
| Joseph Stringer Needham | Buy | $22 | Maintains | Mar 26, 2024 |
| Joseph Stringer Needham | Buy | $14 | Reiterates | Feb 16, 2024 |
| Joseph Stringer Needham | Buy | $14 | Maintains | Nov 7, 2023 |
| Charles Duncan Cantor Fitzgerald | Overweight | $14 | Maintains | Aug 8, 2023 |
When did it IPO
2019
Staff Count
110
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Edward M. Kaye M.D., Ph.D.
Market Cap
$641.4M
In 2023, STOK generated $8.8M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that STOK's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 20 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Stoke Therapeutics (STOK) shows signs of support with a hammer chart pattern, and Wall Street analysts have revised earnings estimates higher, indicating potential for a near-term turnaround.
Why It Matters - Stoke Therapeutics shows potential for recovery with a hammer chart pattern and positive analyst earnings revisions, indicating possible upward momentum and investment opportunity.
Fri, 08 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Wall Street analysts' average price targets suggest a 66.8% upside for Stoke Therapeutics (STOK), supported by positive earnings estimate revisions.
Why It Matters - A 66.8% potential upside in price targets suggests significant growth potential for Stoke Therapeutics, while positive earnings revisions may further boost investor confidence and stock performance.
Tue, 05 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Stoke Therapeutics (Nasdaq: STOK) reported Q3 2024 financial results and updates on zorevunersen, an antisense oligonucleotide aimed at treating Dravet syndrome.
Why It Matters - Stoke Therapeutics' financial results and updates on zorevunersen's development could influence investor sentiment, particularly regarding the company's potential growth and innovation in RNA medicine.
Tue, 05 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Stoke Therapeutics reported a quarterly loss of $0.47 per share, beating the Zacks Consensus Estimate of $0.52, and an improvement from a loss of $0.55 per share a year earlier.
Why It Matters - Stoke Therapeutics' smaller-than-expected loss signals improving financial health, potentially boosting investor confidence and stock performance.
Tue, 29 Oct 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Stoke Therapeutics (STOK) is anticipated to likely beat earnings expectations in its upcoming report, based on key performance indicators.
Why It Matters - Stoke Therapeutics may exceed earnings expectations, indicating strong performance that could boost stock value and investor confidence.
Tue, 10 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Stoke Therapeutics presented data at the European Epilepsy Congress on Zorevunersen (STK-001), showing significant seizure reductions and improvements for Dravet syndrome.
Why It Matters - Stoke Therapeutics’ advancements in Zorevunersen for Dravet syndrome could lead to significant market traction, potentially boosting stock value and attracting investor interest in biotech.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
